Vimarsana
Biggest News Aggregation in the World

Alpmy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alpmy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alpmy Today - Breaking & Trending Today

Astellas Pharma (OTCMKTS:ALPMY) Stock Crosses Below Fifty Day Moving Average of $11.66 - Vimarsana News

Astellas Pharma (OTCMKTS:ALPMY) Stock Crosses Below Fifty Day Moving Average of $11.66

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $11.66 and traded as low as $10.77. Astellas Pharma shares last traded at $10.82, with a volume of 182,653 shares changing hands. Astellas Pharma Price Performance […]

Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Increase in Short Interest - Vimarsana News

Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Increase in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 159,100 shares, an increase of 305.9% from the December 15th total of 39,200 shares. Based on an average trading volume of 554,500 shares, […]

Source: wkrb13.com
Dividend Investors Should Look Abroad. 3 Stocks From Europe and Japan. - Vimarsana News

Dividend Investors Should Look Abroad. 3 Stocks From Europe and Japan.

International equities yield more and cost less on average than U.S. stocks. Legrand, RELX, and Astellas Pharma are among the current prospects.

Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev - Vimarsana News

Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev

By Ben Glickman Merck & Co., Pfizer and Astellas Pharma have received approval from the U.S. Food and Drug Administration for using Keytruda in...

Astellas Pharma (OTCMKTS:ALPMY) Reaches New 1-Year Low at $11.25 - Vimarsana News

Astellas Pharma (OTCMKTS:ALPMY) Reaches New 1-Year Low at $11.25

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as $11.25 and last traded at $11.57, with a volume of 586209 shares trading hands. The stock had previously closed at $11.78. Analysts Set New Price Targets Separately, Jefferies Financial Group cut Astellas […]